<DOC>
	<DOCNO>NCT02833389</DOCNO>
	<brief_summary>This trial evaluate safety , tolerability , pharmacokinetics , pharmacodynamics repeat dose UTTR1147A patient neuropathic diabetic foot ulcer respond adequately standard wound care . Patients across multiple site assign one 4 cohort ( Cohort A , B , C D ) base eligibility criterion randomize receive subcutaneous ( SC ) injection either UTTR1147A placebo 12 week , addition standard wound care .</brief_summary>
	<brief_title>The Safety , Tolerability , Pharmacokinetics , Pharmacodynamics UTTR1147A Participants With Neuropathic Non-Healing Diabetic Foot Ulcers</brief_title>
	<detailed_description />
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>Have diagnosis Type 1 Type 2 diabetes confirm peripheral neuropathy Have adequate circulation foot Have ulcer area screen 5 centimeter square ( cm^2 ) Up date ageappropriate cancer screening per local standard Have current evidence osteomyelitis , cellulitis , evidence systemic infection Have gangrene present part affect foot Known peripheral arterial disease ( PAD ) require revascularization Have glycated hemoglobin A1C ( HbA1c ) level great ( &gt; ) 12 percent ( % ) assess screen Are receive oral parenteral corticosteroid , immunosuppressive , cytotoxic agent Have active malignancy history malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>